La utilidad de un score ecográfico simplificado en la evaluación de pacientes con artritis reumatoidea

Dombret H, Raffoux E, Gardin C. New insights in the management of elderly patients with acute myeloid leukemia. Curr Opin Oncol. 2009;21(6):589-93 DOI: https://doi.org/10.1097/CCO.0b013e3283313e10

Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93(12):1806-13. DOI: https://doi.org/10.3324/haematol.13309

Rathnasabapathy R, Lancet JE. Management of acute myelogenous leukemia in the elderly. Cancer Control. 2003;10(6):469-77. DOI: https://doi.org/10.1177/107327480301000605

Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-87 DOI: https://doi.org/10.1182/blood-2008-07-172007

Büchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27(1):61-9. DOI: https://doi.org/10.1200/JCO.2007.15.4245

Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer. 2005;103(10):2082-90. DOI: https://doi.org/10.1002/cncr.21006

Kantarjian H, O’brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090-8. DOI: https://doi.org/10.1002/cncr.21723